A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

NCT04682431 PHASE1 TERMINATED

This is an open-label, multicenter, First-In-Human (FIH), Phase 1a/1b study of PY159 in subjects with locally advanced (unresectable) and/or metastatic solid tumors that are refractory or relapsed to Standard Of Care (including Checkpoint Inhibitors, if approved for that indication).

Details

Lead sponsor	Ikena Oncology
Phase	PHASE1
Status	TERMINATED
Enrolment	127
Start date	Tue Nov 10 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Aug 31 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Advanced Solid Tumor
• Gynecologic Cancer
• Breast Cancer
• Colorectal Cancer
• Gastric Adenocarcinoma
• Lung Adenocarcinoma
• Pancreatic Cancer
• Head and Neck Cancer

Interventions

• PY159 Single agent dose level 1
• PY159 Single agent dose level 2
• PY159 Single agent dose level 3
• PY159 Single agent dose level 4
• PY159 Single agent dose level 5
• PY159 Single agent dose level 6
• PY159 Single agent dose level 7
• PY159/Pembrolizumab Combination dose level 1
• PY159/Pembrolizumab Combination dose level 2
• PY159/Pembrolizumab Combination dose level 3

Countries

United States